Alder BioPharmaceuticals, Inc. (ALDR) Rating Reiterated by Mizuho
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)‘s stock had its “buy” rating reissued by investment analysts at Mizuho in a report issued on Friday. They presently have a $32.00 price objective on the biopharmaceutical company’s stock. Mizuho’s target price points to a potential upside of 213.73% from the company’s current price.
The analysts wrote, “We received an email from Alder yesterday on its recap of the 18th Congress of the International Headache Society (IHC) meeting as it relates to eptinezumab. What we found as incremental data points are Alder’s interviews with practicing physicians on the advantages of eptinezumab. We believe the IV formulation for eptinezumab is a positive differentiation from other CGRP products in late stage development because of its reimbursement and potentially better compliance.””
A number of other equities analysts have also recently issued reports on the stock. Royal Bank Of Canada began coverage on shares of Alder BioPharmaceuticals in a report on Thursday. They issued an “outperform” rating and a $17.00 target price on the stock. BidaskClub raised Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Credit Suisse Group set a $11.00 price target on Alder BioPharmaceuticals and gave the company a “hold” rating in a report on Thursday, August 24th. Needham & Company LLC reaffirmed a “buy” rating and set a $26.00 price target (down previously from $36.00) on shares of Alder BioPharmaceuticals in a report on Thursday, August 10th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $27.00 price target (down previously from $39.00) on shares of Alder BioPharmaceuticals in a report on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. Alder BioPharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $30.62.
Alder BioPharmaceuticals (ALDR) opened at 10.20 on Friday. Alder BioPharmaceuticals has a 12 month low of $8.60 and a 12 month high of $35.62. The firm’s market cap is $690.67 million. The company has a 50-day moving average price of $9.66 and a 200 day moving average price of $16.05.
Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.67) by $0.19. The business had revenue of $0.68 million during the quarter. During the same quarter in the prior year, the company earned ($0.79) earnings per share. The firm’s revenue was up 518.2% compared to the same quarter last year. Equities research analysts anticipate that Alder BioPharmaceuticals will post ($5.74) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Alder BioPharmaceuticals, Inc. (ALDR) Rating Reiterated by Mizuho” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/17/alder-biopharmaceuticals-inc-aldr-rating-reiterated-by-mizuho.html.
In other news, Director Stephen M. Dow acquired 25,000 shares of the stock in a transaction on Tuesday, July 18th. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $250,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 10.60% of the company’s stock.
Several large investors have recently modified their holdings of ALDR. Teachers Advisors LLC boosted its stake in shares of Alder BioPharmaceuticals by 1.5% during the 4th quarter. Teachers Advisors LLC now owns 76,809 shares of the biopharmaceutical company’s stock valued at $1,598,000 after buying an additional 1,171 shares during the period. Bank of Montreal Can boosted its stake in shares of Alder BioPharmaceuticals by 3,047.2% during the 1st quarter. Bank of Montreal Can now owns 5,602 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,424 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Alder BioPharmaceuticals by 145.2% during the 1st quarter. Russell Investments Group Ltd. now owns 39,579 shares of the biopharmaceutical company’s stock valued at $823,000 after buying an additional 23,437 shares during the period. American Century Companies Inc. boosted its stake in shares of Alder BioPharmaceuticals by 5.7% during the 1st quarter. American Century Companies Inc. now owns 70,486 shares of the biopharmaceutical company’s stock valued at $1,466,000 after buying an additional 3,815 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Alder BioPharmaceuticals by 4.6% during the 1st quarter. Bank of New York Mellon Corp now owns 210,401 shares of the biopharmaceutical company’s stock valued at $4,377,000 after buying an additional 9,218 shares during the period. 76.16% of the stock is owned by institutional investors.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.